← Back to Clinical Trials
Recruiting Phase 1 NCT07286682

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Healthy Participants
Sponsor UCB Biopharma SRL
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 96
Sex ALL
Min Age 18 Years
Max Age 55 Years
Start Date 2025-12-08
Completion 2026-12-13
Interventions
UCB5285Placebo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of single ascending doses of UCB5285 in healthy study participants, including healthy Japanese study participants

Eligibility Criteria

Inclusion Criteria: * For study participants of Japanese origin: study participant who is born in Japan and of Japanese descent as evidenced in appearance and verbal confirmation of familial heritage with all 4 grandparents and both parents born in Japan and has not had a significant change in lifestyle or diet since leaving Japan * For all study participants: * Study participant must be 18 to 55 years of age, inclusive, at the time of signing the informed consent * Study participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * Body weight within 40 kilograms (kg) to 110 kg and body mass index (BMI) within the range of 18 kilograms per meter square (kg/m2) to 30 kg/m2 (inclusive) Exclusion Criteria: * Study participant has a history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, electrocardiogram (ECG), or vital sign th

Related Trials

}
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology